In colorectal cancer, the presence of the KRAS mutation was associated with upregulation of miR-127-3p, miR-92a, and miR-486-3p and downregulation of miR-378, which constituted a miRNA signature capable of predicting colorectal cancers resistant to EGFR antagonists [54]. This evidence concerns the gene KRAS and colorectal cancer.